We would like to inform you that PRISM BioLab will relocate our Tokyo office to the address below, effective January 19, 2026. Please note that our main phone number will remain unchanged. Relocation Date: January 19, 2026 New Address: Nihonbashi Life Science Building 2, Room 401 3-11-5 Nihonbashi-Honcho, Chuo-ku Tokyo 103-0023, Japan Phone: +81-466-53-8383 (Main)...

PRISM BioLab and Talus Bioscience, Inc. are pleased to announce that we have entered into a joint research agreement to discover novel inhibitors targeting transcription factors and protein-protein interactions (PPIs). For more details, please click here.

PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on 17th November, 2025. For more details, please click here (Japanese language PDF).

Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)

PRISM BioLab is pleased to announce that we have achieved the initial milestone in our drug discovery collaboration with Ono Pharmaceutical Co., Ltd. and will receive an upfront payment. For more details, please click here.

PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of PRI-724/OP-724 (generic name: foscelbinib), which has been licensed to Ohara Pharmaceutical Co., Ltd., has been initiated. For more details, please click here (Japanese language PDF).

TOKYO, Japan, October 17, 2025: — PRISM BioLab announces that Eisai Co., Ltd. will present clinical trial results and biomarker exploration data for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 22, 2025....

PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on September 30, 2025. For more details, please click here (Japanese language PDF).

We would like to announce that PRISM BioLab and Servier have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please click here (English language PDF).

We would like to announce that PRISM BioLab and Eli Lilly and Company have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please see the full announcement below: https://contents.xj-storage.jp/xcontents/AS09340/e4067309/8794/4b19/8225/2fb73b3fca54/140120250728521212.pdf